Patients
From January 1st, 2010 to December 31st, 2018, a total of 46 patients aged over 3 years were diagnosed with high risk MB. The median age at diagnosis was 10.6 (range, 5-21) years. There were 33 male and 13 female patients. For biological analyses, 34 (73.9%) of the 46 MB patients were included in molecular analyses. In total, 32 patients received intrathecal MTX and were classified in MTX group, whereas the remaining 14 were treated without intrathecal MTX and were in control group. For the 32 patients in MTX group, 27 (84.38%) had metastatic disease, 3 (9.38%) had diffuse anaplasia, and 3 (9.38%) had residual disease greater than 1.5 cm2. Molecular subgroup classification was available in 28 (87.5%) patients, which assigned patients to WNT (n=0), SHH (n=5), group 3 (n=6), and group 4 (n=17) subgroups.
Among the 14 patients in control group, 8 (57.14%) had metastatic disease, 3 (27.27%) had diffuse anaplasia, and 6 (42.86%) had residual disease greater than 1.5 cm2. Molecular subgroup classification was available in 6 (42.86%) patients, assigning patients to WNT (n=0), SHH (n=2), group 3 (n=1), and group 4 (n=3) subgroups.
The details of these patients are presented in Supplementary Table 1.